Yan-Hui Liu, MD
Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangzhou, China
Fang-Ping Xu, MD, PhD
Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangzhou, China
Jian-Yu Rao, MD
Department of Pathology and Laboratory Medicine, UCLA Medical Center, Los Angeles, CA
Heng-Guo Zhuang, MD
Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangzhou, China
Xin-Lan Luo
Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangzhou, China
Li Li, MS
Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangzhou, China
Dong-Lan Luo, MS
Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangzhou, China
Fen Zhang
Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangzhou, China
Jie Xu
Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangzhou, China
|
|
Keywords: HER2; Breast cancer; Immunohistochemistry;
Fluorescence in situ hybridization
Upon completion of this activity, you will be able to:
- outline the protocol for the HER2 fluorescence in situ hybridization (FISH) test.
- describe the difference between Food and Drug Administration and American Society of Clinical
Oncology/College of American Pathologists guidelines for the HER2 immunohistochemical scoring system for breast
carcinomas.
- address interpretation of results using different criteria and cite factors that may lead to discordant
results between immunohistochemical scoring and FISH for HER2 in breast carcinomas.
|